NEWS
EXPERT PERSPECTIVE
FROM THE LITERATURE
MEDICAL EDUCATION
OUR FACULTY
GLOSSARY10
2020
The prevalence, risks and costs of NASH
NASH is associated with cardiovascular diseases and cardiovascular mortality. Prof Rosano, UK discusses the prevalence, risks and economic costs of NAFLD and NASH. He sheds lights on the risk of obesity that induces many changes. He also reviews countries with higher prevalence, age characteristics and the incidence and progression of the disease
10
2020
Comparison of four non-alcoholic fatty liver disease detection scores in a Caucasian population
Several scores based on easily measurable biochemical and clinical parameters, including the fatty l...
10
2020
Physical Activity, Measured Objectively, is Associated With Lower Mortality in Patients With Nonalcoholic Fatty Liver Disease
D. Kim et al. (Stanford University School of Medicine, Stanford, California, United States) studied ...
03
2020
What do we know about the lipid effects of PPARs ?
Prof Sacks, USA summarises what we know about the PPARs lipid effects. If the strongest evidence is ...
03
2020
A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease
A panel of international experts from 22 countries propose a new definition for the diagnosis of MAF...
03
2020
From NAFLD to MAFLD: when pathophysiology succeeds
Two new position papers convincingly propose that non-alcoholic fatty liver disease needs a new name...
28
2020
Microvesicles as biomarkers in NAFLD : a clinician’s point of view
Prof Rautou, France, sheds light on microvesicles, which reflect apoptosis and cell activation. He ...
28
2020
Non-alcoholic fatty liver disease: correlation with hyperuricemia in a European Mediterranean population.
Several studies have investigated the association between serum uric acid and metabolic syndrome / ...
28
2020
Experimental steatohepatitis: lanifibranor early reduces NASH activity and macrophage infiltration.
In a CDAA-HFD (choline-deficient, amino acid-defined high-fat diet-induced) model, which induces sev...
05
2020
Why are we linking PPAR agonists and lipids ?
Prof Sacks, Harvard Medical School, discusses the link between PPAR agonists and plasma lipid risk ...
05
2020
Metabolic liver disease in diabetes - from mechanisms to clinical trials.
Non-alcoholic fatty liver disease (NAFLD) is tightly associated with the most frequent metabolic dis...
Contact Information
Yann Colardelle / Med Ed GS
27 rue Raffet, 75016 Paris, France
info@mededgs.com
